ERBB2 and breast cancer: utilized diffusion‐weighted MR (magnetic resonance) imaging to compare HER2‐positive and HER2‐negative breast cancer brain metastases and found that the minimum apparent diffusion coefficient value was significantly greater for HER2‐positive lesions in comparison to HER2‐negative lesions [15].